Even before COVID-19 changed the way medicines and medical products are developed around the world, regulators were facing a growing number of challenges.

Life Science companies have demonstrated a strong appetite for artificial intelligence solutions to support both the drug discovery and drug development processes.

The first step to building a custom digital drug development strategy is to create a business case that will reliably predict costs, clearly establish the impact on internal resources and budget, guarantee on-time delivery and ensure leadership buy-in.

Of all the potential drugs being developed today, it’s likely no more than five percent will make it to market.

Anyone in the drug development industry who has recently attended an industry conference, browsed a trade publication or even opened an email is likely to feel overwhelmed by the proliferation of proffered technology solutions.